↓ Skip to main content

Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial

Overview of attention for article published in BMC Pulmonary Medicine, May 2015
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
38 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial
Published in
BMC Pulmonary Medicine, May 2015
DOI 10.1186/s12890-015-0051-x
Pubmed ID
Authors

Marietta Rottenkolber, Rainald Fischer, Luisa Ibáñez, Joan Fortuny, Robert Reynolds, Justyna Amelio, Roman Gerlach, Martin Tauscher, Petra Thürmann, Joerg Hasford, Sven Schmiedl

Abstract

After the SMART trial evaluating the safety of salmeterol (long-acting beta-2-agonist (LABA)) in asthma patients, regulatory actions were taken to promote a guideline-adherent prescribing of LABA only to patients receiving inhaled corticosteroids (ICS). We aim to analyse LABA- and ICS-related prescription patterns after the SMART trial in Germany. Patients documented in the Bavarian Association of Statutory Health Insurance Physicians database (approximately 10.5 million people) were included if they had a diagnosis of asthma and at least one prescription of LABA and/or ICS between 2004 and 2008. Annual period prevalence rates (PPRs) were estimated and Cochrane Armitage tests were used. Highest annual PPRs were found for budesonide and the fixed combination of salmeterol/fluticasone. The proportion of "concomitant LABA and ICS users" increased from 52 to 58% within the study period, whereas for "LABA users without ICS" a slight decrease from 6.5 to 5.4% was found. In 2008, the proportion of patients with at least one quarter with a LABA prescription without concomitant ICS was highest in elderly, male patients (≈20%). In the majority of these patients, a concomitant diagnosis of COPD (i.e. asthma-COPD overlap syndrome [ACOS]) was present. Between 2004 and 2008, we found a moderate increase in guideline-adherent LABA prescribing in a representative German population. Elderly men received a significant number of LABA prescriptions without concomitant ICS probably due to ACOS.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 38 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 7 18%
Student > Bachelor 5 13%
Researcher 4 11%
Student > Ph. D. Student 4 11%
Other 3 8%
Other 6 16%
Unknown 9 24%
Readers by discipline Count As %
Medicine and Dentistry 9 24%
Pharmacology, Toxicology and Pharmaceutical Science 7 18%
Nursing and Health Professions 4 11%
Immunology and Microbiology 2 5%
Social Sciences 2 5%
Other 5 13%
Unknown 9 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 June 2016.
All research outputs
#17,765,638
of 22,816,807 outputs
Outputs from BMC Pulmonary Medicine
#1,255
of 1,913 outputs
Outputs of similar age
#179,880
of 264,482 outputs
Outputs of similar age from BMC Pulmonary Medicine
#25
of 34 outputs
Altmetric has tracked 22,816,807 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,913 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,482 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.